The global automated microbiology market is expected to grow over the forecast period owing to the increasing prevalence of pathogen induced diseases. In the recent years, identification of pathogens with the help of automated microbiology has generated huge momentum, as it helps in early detection of various infectious agents such as parasite, viroid, fungus, prion, bacterium and virus. These agents cause severe diseases like rubella, ebola, chickenpox, measles, mumps, influenza and smallpox. Automated microbiology has gained importance as a result of outbreaks of new diseases as a consequence of adapting and mutating bacteria. The ability to promptly respond to the increasing demand of public health lies in offering accurate, better and rapid identification of diseases and causative pathogens. Rapid technological advancements are also boosting the growth of this market. For instance, STEC test by BioControl Systems that helps in detection of non-O157 serotype of e.coli with the help of molecular and food microbiology technology and BacT/ALERT 3D microbial detection system introduced by bioMeriux. As compared to other microbial detection systems, automated microbiology comes along with advantages such as early detection and easy access system.
Automated microbiology market on the basis of technology is segmented into DNA sequencing; DNA & RNA probe technology, detection techniques, immunoassays, and monoclonal antibodies. Among these, monoclonal antibodies held the largest market share in 2014, owing to their extensive use to develop the clone of the parent cell which is used in the detection of the infected cell or disease. Furthermore, DNA and RNA probe technology is bifurcated into amplification methods and labeling techniques. Detection techniques is further classified into, non-isotopic methods and radioactive methods. Automated microbiology market is segmented on the basis of end-use into biotechnology industries, clinical laboratories, hospitals and blood banks. Among these, clinical laboratories held the largest market share in 2014. The major factor attributing towards the dominance of this segment is the relatively large number of microbiology researches conducted at laboratories for detection of various infectious agents.
Geographically, the automated microbiology market is studied with respect to five regions, which are North America, Europe, Asia Pacific, Latin America and MEA. Among these, North America dominated the market in 2014, owing to the high use of advanced technology in this region, and introduction of advancements in molecular diagnostic tests such as genetic probe. Over the forecast period, Asia pacific will witness lucrative growth as the consequence of rapidly improving healthcare infrastructure over the coming seven years. Moreover, the growing demand for technologically advanced products in this region is expected to further boost the growth of this region.
The major players of the automated microbiology market are Becton Dickinson and Company, Bio-Rad Laboratories, Inc., bioMeriux, Inc., QIAGEN GmbH, Beckman Coulter, Agilent Technologies, Inc., Gene-Probe, Inc., Affymetrix, Inc., and Abbott Laboratories.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.